Seattle genetics, inc. announces health canada approval of adcetris® (brentuximab vedotin) in combination with chemotherapy in frontline cd30-expressing peripheral t-cell lymphoma

Seattle genetics, inc. announced that health canada has approved the supplemental new drug submission that expands the use of adcetris (brentuximab vedotin) in combination with chp (cyclophosphamide, doxorubicin, prednisone) chemotherapy for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (salcl), peripheral t-cell lymphoma-not otherwise specified (ptcl-nos) or angioimmunoblastic t-cell lymphoma (aitl), whose tumours express cd30. the approval is based on positive results of the phase 3 echelon-2 clinical trial that compared adcetris plus chp to chop (cyclophosphamide, doxorubicin, vincristine, prednisone). health canada granted a priority review designation for this submission. adcetris is an antibody-drug conjugate (adc) directed to cd30, which is expressed on the surface of several types of ptcl. in may 2019, health canada approved the supplemental new drug submission that expanded the use of adcetris in combination with avd (adriamycin, vinblastine and dacarbazine) chemotherapy in patients with previously untreated stage iv hodgkin lymphoma (hl) based on the results of the phase 3 echelon-1 clinical trial.
SGEN Ratings Summary
SGEN Quant Ranking